Serum Adiponectin Levels in Three Different Solid Tumors

Abstract

Aim: In the recent clinical trials showed that decreased serum adiponectin levels were associated with several cancer types (breast, prostate, endometrium and colorectal cancers; adiponectin have anti-proliferative and proapoptotic effects on cancer cells, in-vitro. In this study, we aimed to investigate, serum adiponectin levels in the pts with three different cancer types (colorectal, lung and gastric cancer) and healthy controls and the association between BMI, tumor stage and serum adiponectin levels.

Material and Methods: A total of 25 CRC, 18 lung, 18 gastric cancer pts and sex and age matched 18 healthy controls were enrolled to study. Tumor characteristics (stage, grade, surgery and other treatments), clinical and laboratory findings were recorded. 

Results: Mean age was 64.310.6 years in the whole patient group (n=61) and 61.810 years in healthy controls. The mean BMI of the case group was lower than that of the control group (24.54.6 kg/m2 and 27.83.3 kg/m2 , p=0.002). Serum adiponectin levels were significantly decreased in the pts (90.323.8 ng/mL vs 114.844.2 ng/mL, p). Serum adiponectin levels were 87.719.2 and 98.531.6 ng/mL in the CRC and gastric cancer pts. Compared to healthy controls, serum adiponectin levels were significantly decreased in the lung and CRC pts (p values 0.021 and 0.020). A significant positive correlation between serum adiponectin and CRP levels in lung cancer pts (Spearman’s rho=0.560, p=0.016).

Conclusion: Previous studies showed that serum adiponectin levels were decreased in several cancer types including breast, prostate, endometrium and colorectal cancers. ın this study, serum adiponectin levels were decreased in cancer pts, significantly decreased in the pts with CRC and lung cancer. Our research emphasizes the importance of adiponectin levels in cancer patients and sheds light on the work to be done in this direction.

Keywords

• Obesity,Adiponectin,Colorectal Cancer,Gastric Cancer,Lung cancer

Üç Farklı Solid Tümörde Serum Adiponektin Düzeyleri

Abstract

Amaç: Klinik çalışmalar adiposit ile ilişkili bir ürün olan adiponektin düzeylerindeki azalmanın meme kanseri, prostat, endometriyal ve kolorektal kanserleri de içeren çeşitli kanserlerle ilişkisi olduğu, in vitro ortamda adiponektinin kanser hücreleri üzerine antiproliferatif ve proapoptotik etkilerini olduğu bildirilmiştir. Bu çalışmada üç farklı kanser (kolorektal, akciğer, mide kanseri) hastalarında adiponektin düzeylerinin, sağlıklı kontrollerle karşılaştırılması, adiponektin düzeylerinin vücut kitle indeksi (VKİ), tümör evresi ile ilişkilerinin incelenmesi amaçlandı.

Gereç ve Yöntemler: Çalışmaya 25 kolorektal, 18 akciğer, 18 mide kanseri hastası ile yaş ve cinsiyet uyumlu 18 sağlıklı birey kontrol grubu olarak alındı. Olguların tümör özellikleri (evre, grade, cerrahi ve diğer tedaviler) kaydedildi. Olgu ve kontrol grubunun rutin fizik muayene bulguları, hemogram ve biyokimyasal parametreleri kaydedildi ve analizler yapıldı.

Bulgular: Olgu grubu (n=61) yaş ortalaması 64.310.6 yıl, kontrol grubunun (n=18) ise 61.810 yıldı (p=0.29). Olgu grubunun VKİ ortalaması kontrol grubuna göre düşük saptandı (24.54.6 ve 27.83.3 kg/m2 , p=0.002). Olguların serum adiponektin düzeyleri sağlıklı kontrollere göre istatistiksel olarak anlamlı derecede düşüktü (90.323.8 ng/mL karşın 114.844.2 ng/mL, pEn düşük adiponektin düzeyleri akciğer kanserinde (85.619.5 ng/mL) saptandı. Kolon ve gastrik kanserde adiponektin düzeyleri sırasıyla 87.719.2 ve 98.531.6 ng/mL idi. Akciğer ve kolorektal kanserli hastaların serum adiponektin düzeyleri sağlıklı kontrollere göre istatistiksel olarak anlamlı ölçüde düşüktü (sırasıyla p değerleri 0.021 ve 0.020). Akciğer kanserli hastalarda serum adiponektin düzeyleri ile CRP arasında anlamlı pozitif korelasyon saptandı (Spearman’s rho=0.560, p=0.016).

Sonuç: Endometrium, meme, prostat, akciğer ve kolorektal gibi çeşitli kanser tiplerinde adiponektin düzeylerinin azaldığı gösterilmiştir. Bu çalışmada serum adiponektin düzeylerinin tüm kanserlerde azaldığı, kolorektal ve akciğer kanserli hastalardaki bu azalma istatistiksel olarak anlamlı olduğu görüldü. Çalışmamız kanserli hastalarda adiponektin düzeylerinin önemini vurgulamakta ve bu yönde yapılacak çalışmalara ışık tutmaktadır. 

Keywords

• Obezite,Adiponektin,Kolorektal kanser,Gastrik kanser,Akciğer Kanseri

References

1. 1. Perrier S, Jardé T. Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Curr Med Chem. 2012;19:32:5501-12.
2. 2. Mamur BA, Akbaş E, Çolak T, Türkmenoğlu MÖ, Seyit H, Sungur MA. Ralationship between adiponectin and adiponectin receptor 1 gene polymorphisms with colorectal cancer. J Clin Exp Invest 2014;5:4:572-6.
3. 3. Byeon JS, Jeong JY, Kim MJ. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 2010;127:2758–67.
4. 4. Yeqiong Xu, Bangshun He, Yuqin Pan. The roles of ADIPOQ genetic variations in cancer risk: evidence from published studies. Mol Biol Rep 2013;40:1135-44.
5. 5. Carvajal-Carmona LG, Spain S, Kerr D. Common variation at the adiponectin locus is not associated with colorectal cancer risk in the UK. Human Mol Gen 2009;18:1889-92.
6. 6. Wei T, Ye P, Peng X, Wu LL, Yu GY. Circulating adiponectin levels in various malignancies: An updated meta-analysis of 107 studies. Oncotarget. 2016;26;7:30:48671-91.
7. 7. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133-45.
8. 8. Trevellin E, Scarpa M, Carraro A, Lunardi F, Kotsafti A, Porzionato A, Saadeh L, Cagol M, Alfieri R, Tedeschi U, Calabrese F, Castoro C, Vettor R. Esophageal adenocarcinoma and obesity: peritumoral adipose tissue plays a role in lymph node invasion. Oncotarget. 2015; 6:11203-15.

9. 9. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: A review of current evidence. Endocr Rev. 2012;33:4:547-94.
10. 10. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and pr0ogression. Endocr Rev 2011;32:550-70.
11. 11. Van Kruijsdijk RC, Van der Wall E, Visseren FL. Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569–78.
12. 12. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care. 2004;27:10:2450–7.
13. 13. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J. Association between adiponectin and mediators of inflammation in obese women. Diabetes. 2003;52:4:942–7.
14. 14. Viengchareun S, Zennaro M, Pascual L, Lombes M. Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett 2002;532:345-50.
15. 15. Palomer X, Perez A, Blanco-Vaca F. Adiponectin: A new link between obesity, insulin resistance and cardiovascular disease. Med Clin (Barc) 2005;124:388-95.
16. 16. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res. 2003; 9:5699-704. 17. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology. 2005;65:1168-1172.
17. 18. Gu C, Qu Y, Zhang G, Sun L, Zhu Y, Ye D. A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer. Oncotarget. 2015; 6:32205-11.
18. 19. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM, Lu KH. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006; 106:2376-81.
19. 20. Fukumoto J, Otake T, Tajima O, Tabata S, Abe H, Mizoue T, Ohnaka K, Kono S. Adiponectin and colorectal adenomas: self defense forces health study. Cancer Sci. 2008; 99:781-6.
20. 21. Gu L, Cao C, Fu J, Li Q, Li DH, Chen MY. Serum adiponectin in breast cancer: A meta-analysis. Medicine (Baltimore). 2018;97(29):e11433.
21. 22. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R: Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2006; 345:271-9.
22. 23. Zhang L, Wen K, Han X, Liu R, Qu Q: Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway Gynecol Oncol. 2015;137:311-20.
23. 24. Pezzilli R, Barassi A, Corsi MM, Morselli-Labate AM, Campana D, Casadei R, Santini D, Corinaldesi R, D’Eril GM. Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancrea-titis from both chronic pancreatitis and pancreatic neoplasms. Scand J Gastroenterol. 2010;45:93-9.
24. 25. Chen MJ, Yeh YT, Lee KT, Tsai CJ, Lee HH, Wang SN. The promoting effect of adiponectin in hepatocellular carcinoma. J Surg Oncol. 2012;106:181-7.
25. 26. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. British Journal of Cancer. 2006;94:9:1221–5.
26. 27. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K and Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res. 2005;11:466-72.
27. 28. Ferroni P, Palmirotta R, Spila A, Martini F, Raparelli V, Fossile E, Mariotti S, Del Monte G, Buonomo O, Roselli M, Guadagni F. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res. 2007;27:483-9.
28. 29. Chen MW, Ye S, Zhao LL, Wang SY, Li YX, Yu CJ, Xie HJ, Wang YM. Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol. 2012;29:5:3129- 35.
29. 30. Shin E, Park DJ, Kim HH, Won NH, Choe G, Lee HS. Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression. J Cancer Res Clin Oncol. 2013;139:4:709-18.
30. 31. Izadi V, Farabad E, Azadbakht L. Serum adiponectin level and different kinds of cancer: A review of recent evidence. ISRN Oncol. 2012;2012:982769.
31. 32. Saxena A, Chumanevich A, Fletcher E, Larsen B, Lattwein K, Kaur K, Fayad R. Adiponectin deficiency: Role in chronic inflammation induced colon cancer. Biochim Biophys Acta. 2012;1822:4:527-36.
32. 33. Gulcelik MA, Colakoglu K, Dincer H, Dogan L, Yenidogan E, Gulcelik NE. Associations between adiponectin and two different cancers: Breast and colon. Asian Pac J Cancer Prev. 2012;13:1:395-8.
33. 34. Kerenidi T, Lada M, Tsaroucha A, Georgoulias P, Mystridou P, Gourgoulianis KI. Clinical significance of serum adipokines levels in lung cancer. Med Oncol. 2013;30:2:507.
34. 35. Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, Mao C, Wang D, Chen J, Yuan G. Circulating adiponectin levels and the risk of breast cancer: a meta-analysis. Eur J Cancer Prev. 2014;23:158-65.
35. 36. An W, Bai Y, Deng SX, Gao J, Ben QW, Cai QC, Zhang HG, Li ZS. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev. 2012;21:126-33.
36. 37. Vetvik KK, Sonerud T, Lindeberg M. Globular adiponectin and its downstream target genes are up-regulated locally in human colorectal tumors: ex vivo and in vitro studies. Metab Clin Exp 2014;63:672-81.
37. 38. Gornick MC, Rennert G, Moreno V, Gruber SB. Adiponectin gene and risk of colorectal cancer. Br J Cancer. 2011;105:4:562- 4.
38. 39. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005;97:1688–94.
39. 40. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: A meta-analysis of 31 studies with 70 000 events. Cancer Epidemiol Biomarkers Prev 2007;16: 2533–47.
40. 41. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007;8: 395–408
41. 42. Fenton JI, Birmingham JM, Hursting SD, Hord NG. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer 2008;122:2437–45.
42. 43. Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A,- Nifli AP, Tseleni-Balafouta S, Mantzoros CS. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer 2008;15:289–99.
43. 44. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, Ahsan H, Mantzoros C, Pasche B. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008;300:1523–31.
44. 45. Pechlivanis S, Bermejo JL, Pardini B, Naccarati A, Vodickova L, Novotny J, Hemminki K, Vodicka P, Forsti A. Genetic variation in adipokine genes and risk of colorectal cancer. Eur J Endocrinol 2009;160: 933–40.
45. 46. Song M, Gong J, Giovannucci EL, Berndt SI, Brenner H, Chang-Claude J, Curtis KR, Harrison TA, Hoffmeister M, Hsu L, Jiao S, Le Marchand L, Potter JD, Schoen RE, Seminara D, Slattery ML, White E, Wu K, Ogino S, Fuchs CS, Hunter DJ, Tworoger SS, Hu FB, Rimm E, Jensen M, Peters U, Chan AT. Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer. 2015;1;137:154-64.
46. 47. Petridou ET, Mitsiades N, Gialamas S, Angelopoulos M, Skalkidou A, Dessypris N, Hsi A, Lazaris N, Polyzos A, Syrigos C, Brennan AM, Tseleni-Balafouta S, Mantzoros CS. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two casecontrol studies. Oncology 2007;73:261–9.
47. 48. Petridou ET, Sergentanis TN, Antonopoulos CN, Dessypris N, Matsoukis IL, Aronis K, Efremidis A, Syrigos C, Mantzoros CS. Insulin resistance: An independent risk factor for lung cancer? Metabolism 2011;60:1100–6.
48. 49. Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkantonis I, Gratsias I, Syrigos KN. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer 2008;61:391–7.
49. 50. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, Kato K, Hamaguchi T, Shimada Y. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009;44:685–90.
50. 51. Seker M, Bilici A, Sonmez B, Ustaalioðlu BB, Gumus M, Gozu H, Sargin M, Orcun A, Gezen C, Eser M, Bildik N, Salepci T. The association of serum adiponectin levels with histopathological variables in gastric cancer patients. Med Oncol 2010;27:1319–23.
51. 52. Seker M, Bilici A, Guler DO, Ustaalioglu BB, Gozu H, Erkal FY, Sonmez B, Karaduman M, Kefeli U, Yildirim E, Salepci T, Gumus M. Tissue and serum adiponectin levels in patients with gastric cancer: Are there any correlations between adiponectin levels and histopathological variables? Hepatogastroenterology 2011;58:1841–6.
52. 53. Bauche IB, Ait El Mkadem S, Rezsohazy R, Funahashi T, Maeda N, Miranda LM, Brichard SM. Adiponectin downregulates its own production and the expression of its AdipoR2 receptor in transgenic mice. Biochem Biophys Res Commun. 2006; 345:1414-24.
53. 54. Qi L, Rimm E, Liu S, Rifai N, Hu FB. Dietary glycemic index, glycemic load, cereal fiber, and plasma adiponectin concentration in diabetic men. Diabetes Care. 2005;28:1022-28.
54. 55. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8:731-7.